22 completed, 9 terminated, 4 withdrawn, 2 recruiting. 39 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 39 | Completed 22, Terminated 9, Withdrawn 4, Recruiting 2, Active not recruiting 1, Unknown 1 |
| Phase 1 | 2 | Completed 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow pasireotide: new trials by email Literature Review of pasireotide trials Research Report on pasireotide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor Signifor - Desmoplastic Small Round Cell Tumor, Synovial Sarcoma | Phase 2 | Recruiting | University Hospital Heidelberg | 28 | 2024-12-19 | 2025-01-13 |
| A Study of Pasireotide in People With Prolactinoma Pasireotide, SF-36 and HADS - Prolactin-Producing Pituitary Tumor | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 10 | 2024-02-27 | 2026-03-04 |
| Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia Pasireotide Diaspartate - Post-Bariatric Hypoglycemia | Phase 2 | Active not recruiting | RECORDATI GROUP | 93 | 2024-01-04 | 2026-09-17 |
| Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis Pasireotide 0.9 MG/ML, Saline water - Peritoneal Carcinomatosis | Phase 2 | Terminated | Gustave Roussy, Cancer Campus, Grand Paris | 6 | 2020-09-03 | 2024-02-08 |
| Pasireotide in Hyperinsulinemic Hypoglycemia Pasireotide 0.6Mg Solution for Injection, Saline Solution - Congenital Hyperinsulinism, Insulinoma | Phase 2 | Withdrawn | Montefiore Medical Center | 2017-04-01 | 2021-05-14 | |
| Reduction by Pasireotide of the Effluent Volume in High-output Enterostomy in Patients Refractory to Usual Medical Treatment Pasireotide, Placebo - Enterostomy | Phase 2 | Completed | Hospices Civils de Lyon | 57 | 2016-12-13 | 2025-12-19 |
| Safety and Efficacy Study of SOM230 s.c. in Cluster Headache SOM230, Placebo - Cluster Headache - Episodic and Chronic | Phase 2 | Terminated | Novartis Pharmaceuticals | 28 | 2016-10-31 | 2021-01-05 |
| SOM230 Ectopic ACTH-producing Tumors Pasireotide - Ectopic ACTH Syndrome | Phase 2 | Withdrawn | Cedars-Sinai Medical Center | 2015-12-01 | 2018-01-26 | |
| Pasireotide in Prevention of GI Toxicity Pasireotide - Hematological Malignancies | Phase 2 | Completed | Anthony Sung, MD | 37 | 2015-01-21 | 2021-11-17 |
| Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Pasireotide with or without cabergoline - Cushings Disease | Phase 2 | Terminated | Novartis Pharmaceuticals | 68 | 2014-03-06 | 2020-09-18 |
| 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA Trial Pasireotide LAR, Everolimus, Pasireotide LAR and Everolimus Combination - Neuroendocrine Carcinoma of the Lung and Thymus | Phase 2 | Completed | Novartis Pharmaceuticals | 124 | 2013-08-16 | 2021-04-02 |
| Phase II Study Evaluating Efficacy, Safety and Pharmacokinetics of Pasireotide in Patients With Dumping Syndrome SOM230 - Dumping Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 43 | 2013-01-08 | 2017-05-10 |
| Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism Pasireotide LAR - Acromegaly, Pituitary Gigantism | Phase 2 | Completed | Novartis Pharmaceuticals | 33 | 2012-10-16 | 2019-09-16 |
| Phase II Trial of SOM230 in Patients With Unresectable Hepatocellular Carcinoma SOM230 - Hepatocellular Carcinoma | Phase 2 | Completed | Lynn Feun | 20 | 2012-07-01 | 2017-07-12 |
| Efficacy of Medical Treatment With SOM230 LAR in Patients With Primary Inoperable Thymoma and/or With Local Recurrent Thymoma to Reduce Tumor Size SOM230 LAR - Primary Inoperable Thymoma, Local Recurrent Thymoma | Phase 2 | Completed | Prof. Dr. Berthold Schalke | 16 | 2012-03-01 | 2018-02-05 |
| Pasireotide for the Treatment of Gastrointestinal Angiodysplasia in Endoscopic Treatment Failure Pasireotide, Placebo - Angiodysplasia | Phase 2 | Completed | Robert Benamouzig | 24 | 2012-03-01 | 2015-12-07 |
| SOM230 Alone or in Combination With RAD001 in Patients With Medullary Thyroid Cancer SOM230 alone or in combination with RAD001. - Medullary Thyroid Cancer | Phase 2 | Completed | Federico II University | 19 | 2012-02-01 | 2016-04-25 |
| Everolimus and Pasireotide (SOM230) in Patients With Advanced or Metastatic Hepatocellular Carcinoma Everolimus, Pasireotide - Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | UNC Lineberger Comprehensive Cancer Center | 24 | 2011-12-01 | 2016-04-07 |
| SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma SOM230, Bortezomib, Dexamethasone - Multiple Myeloma in Relapse, Multiple Myeloma | Phase 2 | Withdrawn | University of Pittsburgh | 2011-12-01 | 2016-02-12 | |
| Docetaxel, Prednisone, and Pasireotide in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer docetaxel, pasireotide, prednisone - Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer | Phase 1 / Phase 2 | Completed | Barbara Ann Karmanos Cancer Institute | 18 | 2011-10-01 | 2021-03-25 |
Showing 20 of 39. Sign in to see all of them.
Pituitary Neoplasms (4) · Acromegaly (3) · ACTH Syndrome, Ectopic (2) · Carcinoid Tumor (2) · Carcinoma, Hepatocellular (2) · Dumping Syndrome (2) · Multiple Myeloma (2) · Nelson Syndrome (2) · Pituitary ACTH Hypersecretion (2) · Prostatic Neoplasms (2) · Adrenocortical Hyperfunction (1) · Angiodysplasia (1) · Breast Neoplasms (1) · Bronchiolitis Obliterans Syndrome (1) · Carcinoma (1)
Novartis Pharmaceuticals (10) · Memorial Sloan Kettering Cancer Center (2) · Alliance Pour La Recherche en Cancerologie (1) · Anthony Sung, MD (1) · Barbara Ann Karmanos Cancer Institute (1) · Cedars-Sinai Medical Center (1) · Emory University (1) · Federico II University (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · H. Lee Moffitt Cancer Center and Research Institute (1) · Hospices Civils de Lyon (1) · Lynn Feun (1) · Milton S. Hershey Medical Center (1) · Montefiore Medical Center (1) · NYU Langone Health (1)
United States (26) · France (11) · Germany (9) · Italy (7) · Belgium (5) · United Kingdom (5) · Spain (4) · Brazil (3) · Netherlands (3) · Argentina (2) · Australia (2) · Greece (2) · Mexico (2) · Canada (1) · Colombia (1)
Annamaria Colao (1) · Anthony Sung, MD (1) · Berthold Schalke, Prof. Dr. (1) · David L Kleinberg, MD (1) · Eliza Geer, MD (1) · Erika Brutsaert, M.D., M.P.H. (1) · Giampaolo Talamo, MD (1) · Hanna Sanoff, MD (1) · Jan Tack, M.D., Ph.D. (1) · Jianqing Lin, MD (1) · John Newell-Price (1) · Jonathan Strosberg, M.D. (1)
PMID 20410233, PMID 23529827, PMID 23733372, PMID 23943009, PMID 25376618, PMID 27280398, PMID 29074099, PMID 29313180, PMID 29572709, PMID 35427770, PMID 37876540, PMID 40934647
2004 (2), 2008 (2), 2009 (1), 2019 (1)